The Model That Changed Biotech
Twenty years ago, a credible pharmaceutical development programme needed laboratories, equipment, and scientists on the payroll. The idea that a five-person team could advance a drug candidate from lead optimisation to Phase II without owning a single centrifuge would have seemed implausible.
Today it is routine. The virtual biotech model, built on outsourcing relationships with CDMOs, CROs, and specialist consultants, has become one of the dominant organisational forms in early-stage pharmaceutical development. It allows small teams to access world-class scientific and manufacturing capabilities without the capital overhead, and it lets investors fund science rather than infrastructure.
It also fails regularly, for predictable reasons that have nothing to do with the science.
What Goes Wrong in Virtual Biotech Programmes
Too Many Vendors, Not Enough Oversight
The instinct of many virtual biotech teams is to find the best vendor for each individual piece of work. Best formulation house for development, best CRO for animal studies, best CMO for manufacturing. The result is a programme spread across five or six organisations with no single point of accountability and a coordination overhead that consumes the management team.
No Internal CMC Expertise
A virtual biotech can outsource the execution of CMC work. It cannot outsource the judgement about what CMC work is needed. Without someone on the team who understands what a regulator will expect to see in Module 3, the programme can spend months generating data that does not answer the right questions.
The Tech Transfer That Should Not Have Existed
Many virtual biotechs develop a molecule with one vendor, then transfer it to a different GMP manufacturing partner because the first vendor does not have GMP capability. Every tech transfer is a risk event. Data is interpreted by new people, processes are reproduced on different equipment, and unexpected results emerge. The transfer that could have been avoided by choosing an integrated partner from the start costs months and money to resolve.
What Successful Virtual Biotechs Do Differently
| Success Factor | What It Looks Like in Practice |
| Choose an integrated partner early | Select a CDMO with development and GMP manufacturing capability at the start; avoid planned tech transfers between development and manufacturing |
| Keep CMC expertise internal | Hire or retain a Head of CMC or CMC consultant with regulatory filing experience; do not rely on the CDMO to own regulatory strategy |
| Define deliverables, not activities | Contract for outcomes (Phase I CMC package) rather than activities (12 months of stability work); gives the CDMO flexibility to design the most efficient programme |
| Build in formal decision gates | Schedule quarterly scientific reviews where the programme strategy is assessed against the data, not just the timeline |
| Use project management tools the CDMO actually supports | Do not assume the CDMO will use your project management system; agree on reporting format and frequency before work starts |
| Plan for the unexpected | Build contingency time and budget into the plan; virtual programmes with no slack are brittle when something goes wrong |
The Integrated CDMO as a Virtual Biotech’s Scientific Department
For a five-person virtual biotech, the CDMO is not just a service provider. It is, functionally, the scientific organisation. The quality of the science that goes into the programme, the data generated, the decisions made, the regulatory strategy pursued, is largely determined by the quality and engagement of the CDMO team.
This is why the consultative tone that characterises good CDMO partnerships matters more for virtual biotechs than for large pharma. A CDMO that executes instructions without pushing back when the science suggests a different approach is not providing the partnership a virtual biotech needs. A CDMO that raises the question about polymorph stability before the first GMP batch is planned, that flags the dissolution method issue before the IND is filed, is providing something genuinely valuable.
How Ardena Supports Virtual Biotech Programmes
Ardena’s model is particularly well suited to virtual biotech programmes. The integrated multi-site network covers solid state research, formulation development, analytical services, GMP manufacturing, bioanalysis, and regulatory support under a single project management framework. For a virtual biotech that does not have scientific departments of its own, Ardena provides the depth of capability that would otherwise require five separate vendor relationships.
